Emergence of psychosis in Alzheimer’s disease linked to elevations in p-tau181
Jul 01, 2024
An increase in plasma p-tau181 levels was seen in patients with incident psychosis over follow-up versus those with psychosis at baseline.
Cognitive impairment delayed with genetic variant
Jun 20, 2024
The onset of cognitive impairment was delayed among those heterozygous for the apolipoprotein E3 Christchurch variant.
FDA approves new drug to treat Alzheimer’s
Jul 02, 2024
In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...